Starts in 1 week from now
LocationHäme EU Office - Brussels
Strengthening European Defence and Security
DEFINE Ecosystem – Paving the Way to Defence Business Excellence in Häme, Finland
The Role of Stakeholders – Regions, Cities, Companies, and Academia in Building a Successful Innovation Defence Ecosystem
Defence Innovation Network Finland (DEFINE), initiated by the City of Riihimäki in Finland, is an international, high-level defence and security industry network. As the leading defence ecosystem, DEFINE brings together high-potential startups, greatest talents and end-users to create innovations that benefit both military and society as a whole.
This seminar will explore the critical need to boost the EU’s security and defence capacity, build defence-related ecosystems, and examine the role of key stakeholders—regions, cities, companies, and academia—in developing a successful ecosystem. Additionally, this event will provide insights into EU funding opportunities for defence and security initiatives.
Please register at the latest on Tuesday 3.6.2025 via the link below.
This seminar is free of charge and in person. Since the number of seats is limited, please secure your place and register early.
Please note that if the maximum number of participants is reached before 3 June, the registration form will be closed early.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital, Industry & Space Climate, Energy, Mobility EIC EIE
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.